Chemical Formula: C30H30F2N6O3
Chemical Formula C30H30F2N6O3
Found 2 metabolite its formula value is C30H30F2N6O3
Sotorasib
D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
Sotorasib
A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
